Chart-Typ:
Zeitraum:
| Day One Biopharmaceuticals, Inc.: Day One Reports First Quarter 2024 Financial Results and Corporate Progress | OJEMDA (tovorafenib) launch underway following U.S. FDA accelerated approval for relapsed or refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG) First prescriptions received in the U.S. BRISBANE... ► Artikel lesen |
| Day One Biopharmaceuticals, Inc.: Day One's OJEMDA (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor | First and only FDA-approved type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation RAPNO LGG overall response rate... ► Artikel lesen |
| Day One Biopharmaceuticals, Inc.: Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress | PDUFA target action date for tovorafenib NDA in relapsed or progressive pLGG remains set for April 30, 2024 Phase 2 FIREFLY-1 tovorafenib registrational data published in Nature Medicine Ended 2023... ► Artikel lesen |
| CG Oncology Inc.: Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer | - Phase 3 BOND-003 study results showed sustained, durable complete responses over 12 months with novel investigational oncolytic immunotherapy - - Company will hold an investor conference call today... ► Artikel lesen |
| CG Oncology: Triumphaler Börsengang - Aktie zieht mächtig an | CG Oncology hat bei seinem Gang an die Nasdaq einen fulminanten Börsenstart hingelegt, der die Erwartungen deutlich übertraf. Das Engagement führender Biotech-Investoren unterstreicht dabei die vielversprechende... ► Artikel lesen |
| Irres Biotech-IPO: Newcomer CG Oncology explodiert knapp 96 Prozent | Mit dem amerikanischen Krebs-Spezialisten CG Oncology ist das erste Biotechnologie-IPO des Jahres 2024 an der Nasdaq am Donnerstag erfolgreich über die Bühne gegangen. Das Interesse an dem Newcomer... ► Artikel lesen |
| Recursion Pharmaceuticals, Inc.: Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer | Dr. Khan, formerly the Chief Data Science Officer and Global Head of Strategy and Portfolio, Innovative Medicine R&D at Johnson & Johnson (J&J), will also join Recursion's Board of DirectorsSALT LAKE... ► Artikel lesen |
| Recursion Pharmaceuticals, Inc.: Recursion Announces Plans to Open New Office in London | Appoints Michael Bronstein as Scientific Advisor and launches recruiting effort to fill the first 20 open roles across technology and biology, establishing a hub for world-class TechBio talent in the... ► Artikel lesen |
| Recursion Pharmaceuticals: Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2023 Financial Results | Multiple clinical programs from Recursion's first generation platform are on track to read out Phase 2 data in H2 2024 and H1 2025 with additional second generation programs approaching IND in the... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
